This report was first published by Endpoints News. To see the original version, click here
Pfizer said it plans to start 15 new studies in obesity next year, many of them in Phase 3, as it seeks to replace about $17 billion in lost revenue by the end of the decade.
Most of those trials will come out of Pfizer’s recent deal for Metsera and its weight loss assets, which it acquired for as much as $10 billion earlier this year.
您已阅读12%（426字），剩余88%（3042字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。